Report Highlights

Prostate Cancer Treatment in the U.S.: Market Overview

The U.S. prostate cancer treatment market was valued at USD 10.6 billion in 2024 and is forecast to reach USD 15.9 billion by 2032. Demand is anchored by roughly 300,000 new diagnoses annually, according to the American Cancer Society, and by a pathway spanning surgery, radiation, androgen deprivation and newer androgen receptor inhibitors. Private pharmaceutical innovators lead therapeutic development, while Medicare, administered by the Centers for Medicare and Medicaid Services (CMS), sets the price and access conditions that determine how quickly new agents reach patients.

Government has been the dominant force in the coverage and pricing layer, whereas the private sector has led therapeutic innovation. The National Cancer Institute funds the cooperative trial networks that establish evidence standards, and the Department of Veterans Affairs operates one of the largest integrated prostate care systems, shaping purchasing at scale. Johnson & Johnson, Astellas and Bayer drove the shift from first-generation antiandrogens to next-generation androgen receptor inhibitors, following the 2011 abiraterone and 2012 enzalutamide approvals that redefined metastatic castration-resistant care.

Policy-Driven Growth in U.S. Prostate Cancer Care

The Inflation Reduction Act of 2022 (Public Law 117-169) is the most consequential federal intervention in this market. Its Part D redesign capped beneficiary out-of-pocket drug spending at USD 2,000 in 2025, removing a major barrier for oral androgen receptor inhibitors such as Xtandi, Erleada and Nubeqa. Simultaneously, the Act's Medicare Drug Price Negotiation Program selected enzalutamide for the second cycle, with negotiated prices effective 1 January 2027. The mechanism is direct: lower cost-sharing expands prescription fill rates, while negotiated prices compress manufacturer net revenue without eliminating volume.

Two further mechanisms add demand. CMS's Outpatient Prospective Payment System provides separate payment for diagnostic radiopharmaceuticals, which underpins PSMA PET imaging, the staging gateway for Novartis's Pluvicto. Pluvicto, first approved by the FDA in March 2022 and expanded in March 2025 to patients before taxane chemotherapy, operates within the review commitments of the Prescription Drug User Fee Act VII (FY2023–FY2027). Each approval converts imaging volume into therapy volume, expanding the eligible patient pool.

Regulatory Barriers and Compliance Costs

Radioligand therapies face a distinct licensing layer. The Nuclear Regulatory Commission, and the Agreement State agencies that administer licensing in most states, regulate byproduct material under 10 CFR Part 35 for medical use, requiring radiopharmacies and nuclear medicine departments to obtain and amend licences before handling lutetium-177. The FDA separately requires current good manufacturing practice under 21 CFR Parts 210 and 211, and PET drug requirements under 21 CFR Part 212 govern PSMA imaging agents. Licence amendments and site qualifications commonly add several months before a new site can dose patients.

Medicare Advantage plans present a second barrier. CMS final rule CMS-4201-F, finalised in April 2023 and effective for 2024, requires Medicare Advantage organisations to follow traditional Medicare coverage criteria, so plans cannot impose stricter utilisation rules than fee-for-service Medicare. Manufacturers also face the federal Anti-Kickback Statute, enforced by the HHS Office of Inspector General, which constrains copay assistance design. Compliance teams therefore spend significant resources on OIG-compliant patient support programmes, adding administrative cost to every launch.

Policy-Created Opportunities in the United States

The Medicare Drug Price Negotiation Program creates a dated opening. Part B drugs become eligible for selection for the 2028 price applicability year, with CMS selection due by 1 February 2026, bringing physician-administered products such as leuprolide depots into scope. Manufacturers that model negotiated Part B prices early can reposition injectable androgen deprivation products toward oral or radiotherapy alternatives before the 2028 ceiling applies.

The CMS Innovation Center's Enhancing Oncology Model, launched in July 2023 for six years, rewards practices that reduce avoidable hospital utilisation for patients on systemic therapy. This creates demand for remote monitoring and oral agents that shorten infusion chair time. Separately, the Cancer Moonshot programme, funded under the 21st Century Cures Act of 2016, supports NCI biomarker trials that generate companion diagnostics for BRCA and homologous recombination testing used with PARP inhibitors such as Rubraca.

Market at a Glance

Leading Market Participants

• Johnson & Johnson
• Astellas Pharma
• Pfizer
• Bayer
• Novartis
• AstraZeneca
• Sumitomo Pharma
• Telix Pharmaceuticals
• Lantheus
• Intuitive Surgical

Regulatory and Policy Environment

The primary legislative architecture comprises the Federal Food, Drug, and Cosmetic Act, administered by the FDA; Title XVIII of the Social Security Act governing Medicare; and the Inflation Reduction Act of 2022 (Public Law 117-169), which created the Medicare Drug Price Negotiation Program. Key compliance requirements include FDA confirmatory trial obligations for accelerated approvals under the Food and Drug Omnibus Reform Act of 2022 (Public Law 117-328), NRC or Agreement State licensing for radiopharmaceuticals, and CMS-4201-F standards for Medicare Advantage coverage. Upcoming changes include the 1 February 2026 selection of Part B drugs and the reauthorisation of PDUFA VII before its 30 September 2027 expiry.

Compared with regional peers, the U.S. framework is distinctive. Canada relies on the Patented Medicine Prices Review Board and pan-Canadian Pharmaceutical Alliance negotiations, with Health Canada approval preceding price review. The European Union's Health Technology Assessment Regulation, Regulation (EU) 2021/2282, applies Joint Clinical Assessments to oncology medicines from 12 January 2025, centralising comparative efficacy evidence before national reimbursement. Unlike these systems, the U.S. sets prices through statutory negotiation and market-based Part D formularies rather than central HTA gatekeeping.

Long-Term Policy Outlook for U.S. Prostate Cancer Care

By 2032 the most significant change will be Part B price negotiation, which will reshape the economics of physician-administered prostate drugs and radioligand therapies. Medicare's negotiated enzalutamide prices, effective 1 January 2027, will set a benchmark that manufacturers of abiraterone, apalutamide and darolutamide must price against in Part D contracting. Generic entry will continue to erode branded hormonal therapy, with generic abiraterone already established across the oral market.

Policy will also reward earlier-stage intervention. The U.S. Preventive Services Task Force, whose 2018 PSA screening recommendation remains a Grade C individual-decision standard for men aged 55 to 69, is expected to update guidance as biomarker evidence matures. Earlier detection will move diagnosis toward localised disease, expanding the pool eligible for surgery, radiotherapy and PSMA-directed imaging.